Vaccine for Prevention hryppa ynaktyvyrovannaya, Azoksymera bromide | Flupol plus susp. for v / m and s / c input. syringe 0, 5 ml

Special Price $17.46 Regular Price $25.00
In stock
SKU
BID495132
349.2 Reward Points will be used to purchase this product
Pharmacological action

The vaccine causes the formation of a high level of specific immunity against influenza. The protective effect after vaccination, as a rule, occurs after 8-12 days and lasts up to 12 months, including in the elderly. Protective titers of antibodies to influenza viruses after vaccination of people of different ages are determined in 75-95% of those vaccinated.

The inclusion of the PolyoxidoniumВ® immunomodulator, which has a wide range of immunopharmacological effects, in the vaccine preparation, provides an increase in the immunogenicity and stability of antigens, improves immunological memory, significantly reduces the vaccination dose of antigens, and increases the body's resistance to other infections by correcting the immune status.
Pharmacological action

The vaccine causes the formation of a high level of specific immunity against influenza. The protective effect after vaccination, as a rule, occurs after 8-12 days and lasts up to 12 months, including in the elderly. Protective titers of antibodies to influenza viruses after vaccination of people of different ages are determined in 75-95% of those vaccinated.

The inclusion of the PolyoxidoniumВ® immunomodulator, which has a wide range of immunopharmacological effects, in the vaccine preparation, provides an increase in the immunogenicity and stability of antigens, improves immunological memory, significantly reduces the vaccination dose of antigens, and increases the body's resistance to other infections by correcting the immune status.

Indications

Specific prophylaxis of influenza in children from 6 months of age, adolescents and adults with no age limit.

The contingents to be vaccinated. The vaccine is especially indicated: For people at high risk of complications from influenza: older than 60 years of age for preschool children,

schoolchildren, adults and children often suffering from acute respiratory infections, suffering from chronic somatic diseases, including diseases and malformations of the central nervous system, cardiac vascular and broncho-pulmonary systems, bronchial asthma, chronic kidney diseases, diabetes, metabolic diseases, autoimmune diseases, allergic diseases (except for allergy to chicken proteins), chronic anemia, congenital or acquired immunodeficiency, HIV-infected

Persons by profession who are at high risk of contracting the flu or contracting other persons: health workers, educational workers, social services, transport, trade , police, military personnel, etc.

Contraindications

Allergic reactions to chicken protein and components of the

vaccine Allergic reactions to previously administered flu vaccines

Acute febrile illness or exacerbation of a chronic disease. (Vaccination is carried out after recovery or during remission)

Light ARVI, acute intestinal diseases (vaccination is carried out after normalization of temperature).

Special instructions

On the day of vaccination, vaccinees should be examined by a doctor (paramedic) with mandatory thermometry. At temperatures above 37.0 РC, vaccination is not carried out.

The drug is not suitable for use in ampoules, vials, syringe doses with impaired integrity or labeling, with a change in physical properties (color, transparency), with an expired Expiration, violation of the requirements for storage conditions.

The vaccine is not allowed to be administered intravenously

Influence on the ability to drive a car, or the operation of machines and mechanisms

Influenza® does not affect the ability to drive a car, or control machines and mechanisms.

Composition

In one dose (0.5 ml) contains:

Active ingredients:

Influenza virus antigen type

A (N1H1) * with hemmaglutin content - 5 Ојg

Influenza virus antigen type

A (N3N2) * with hemmagglutinin - 5 Ојg

Influenza virus type B *

g with В® (Azoximera bromide) - 500 mcg

Auxiliary components:

Phosphate-buffered saline - up to 0.5 ml.

does not contain a preservative.

* Influenza virus antigen strains - as recommended by the WHO for the current epidemic season.

Dosage and administration

Vaccination is carried out annually in the autumn-winter period. Vaccination is possible at the beginning of the epidemic rise in the incidence of influenza.

Children over 3 years old, for adolescents and adults, the vaccine is administered intramuscularly or deeply subcutaneously in the upper third of the outer surface of the shoulder (in the deltoid muscle), for young children - in the anterolateral thigh surface intramuscularly.

For children from 6 to 35 months old, 0.25 ml twice, with an interval of 3-4 weeks.

For children older than 36 months and adults, the vaccine is administered once at a dose of 0.5 ml.

Previously unaffected influenza and unvaccinated children, the vaccine may be administered twice with an interval of 3-4 weeks.

Patients with immunodeficiency and receiving immunosuppressive therapy may receive the vaccine twice in 0.5 ml with an interval of 3-4 weeks.

Before use, the vaccine should be kept at room temperature and shaken well. Remove the protective cap from the needle and remove air from the syringe, holding it upright with the needle up and slowly pressing the piston.

To immunize children who are shown to be given 0.25 ml (1/2 dose) of the vaccine, half the contents of the syringe must be removed by pushing the plunger down to the special risk marked on the syringe body or until a red mark is printed on the edge of the label, and Inject the remaining 0.25 ml.

Opening of ampoules and vials and the vaccination procedure is carried out under strict aseptic and antiseptic rules: before opening, the ampoule knife, the neck of the ampoule, or the cork of the vial are wiped with cotton wool dampened with 70% ethyl alcohol, the vial is opened, or the rubber cork of the vial is punctured with a needle, disposable syringe and remove excess air from the syringe. Wipe the skin with alcohol at the injection site. The drug is in an open ampoule, or vial is not subject to storage.

Side effects

The vaccine is a highly purified preparation, well tolerated by children and adults.

Frequent (> 1/100 <1/10). Local reactions in the form of pain, hyperemia, compaction and edema at the injection site. General reactions: malaise, weakness, low-grade fever

Infrequent (> 1/1000 <1/100) General reactions in the form of a runny nose, sore throat, headache and fever above subfebrile

These reactions usually go away on their own within 1-2 days.

Rare (> 1/10000 <1/1000) Allergic reactions, including the immediate type

Very rare (> 1/10000)

From the nervous system: neuralgia, paresthesia, neurological disorders

from the musculoskeletal system: myalgia

The patient should be informed of the need to inform the doctor of any adverse reactions expressed or not indicated in these instructions

Storage conditions

Store in a dark place at a temperature of 2 РC to 8 РC.

Keep out of the reach of children!

Do not freeze! The drug, subjected to freezing, is not subject to use.

Shelf life

1 year. An expired drug is not to be used.

Active ingredient

Budesonide, Azoximer bromide

lekarstvennaja form

suspensions for

Submit your review to Earn 10 Reward Points click here to login

Write Your Own Review
You're reviewing:Vaccine for Prevention hryppa ynaktyvyrovannaya, Azoksymera bromide | Flupol plus susp. for v / m and s / c input. syringe 0, 5 ml

 Job in company (10-20 minutes a day | 400 - 1200 USD)! 

We are looking for partners!

 If you have PayPal and you are ready to earn in our team - contact us: [email protected] 

Copyright © 2011-2024 Buy-Pharm, Inc. All rights reserved.